ENA-001

Phase 2Small molecule

EEnalare Therapeutics Inc.

ENA-001 is one of 6 small molecule programs targeting Respiratory Depression. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory DepressionNot yet recruiting

Respiratory DepressionPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Respiratory Depression

#DrugCompanyPhaseTrials

Narcan

SScienture

Approved

2 2

Duragesic

CCephalon

Approved

1 3

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 4

Anerem

AAcacia Pharma Ltd

Approved

1 5

Dilaudid

RRhodes Pharmaceuticals, L.P.

Preclinical

1 6

ENA-001

EEnalare Therapeutics Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Respiratory Depression

NCT06137638

Clinical

Trials by Indication[1]

Respiratory Depression2 trials

ENA-001 for Post Operative Respiratory Depression (PORD)

Not yet recruiting·EEnalare Therapeutics Inc.·Phase 2·NCT06137638·200 enrolled

A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENA-001 Administered as Intravenous (IV) and Intramuscular (IM) Doses

Completed·EEnalare Therapeutics Inc.·Phase 1·NCT06967259·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ENA-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ENA-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ENA-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Enalare Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEnalare Therapeutics Inc.

ENA-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Respiratory Depression2 trials

References

Drug Info

Quick Facts

Related News